Drugs / H5 AC-Anhui RNA Vaccine
H5 AC-Anhui RNA Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07019883 | Jun 2025 → May 2026 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5 AC-Anhui RNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07019883 ↗ |
| Known as | H5 AC-Anhui RNA | “The primary objective is to assess the safety of two doses of H5 AC-Anhui RNA vaccine or H5-Astrakhan RNA vaccine administered intramuscularly in healthy adults (18-49 years).” NCT07019883 ↗ |
| Known as | H5 Antigenically Central (AC)-Anhui RNA Vaccine | “Healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 Antigenically Central (AC)-Anhui RNA Vaccine at 12.5 mcg on...” NCT07019883 ↗ |
| Modality | Messenger RNA (mRNA) | “A nucleoside-modified mRNA vaccine encoding a stabilized, antigenically central hemagglutinin (HA) from influenza A(H5), based on A/Anhui/1/2005 (clade 2.3.4) with...” NCT07019883 ↗ |
| Route | Intramuscular | “The 2119-nt mRNA is encapsulated in lipid nanoparticles (LNPs) for intramuscular delivery.” NCT07019883 ↗ |